Rezūm therapy: Outcomes of symptom relief and quality of life in benign prostatic obstruction with three-year followup
Abstract
INTRODUCTION
This study evaluated the long-term efficacy and safety of Rezūm water vapor thermal therapy (WVTT) for treating lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The objective was to assess the durability of symptom relief and sustained LUTS improvement over a three-year followup in a real-world, multicenter cohort.
METHODS
A prospective registry was maintained at two high-volume international centers for men undergoing Rezūm therapy between April 2019 and October 2024. All participants had baseline clinical data recorded, including BPH history, uroflowmetry parameters (peak flow rate [Qmax] and postvoid residual [PVR]), and validated questionnaires (International Prostate Symptom Score [IPSS], IPSS quality of life [QoL], BPH Impact Index [BPHII], International Index of Erectile Function [IIEF-15], and Male Sexual Health Questionnaire for Ejaculatory Dysfunction [MSHQ-EjD]).
RESULTS
A total of 712 men with at least one year of followup were analyzed. The mean age was 67.2 years (stanadrad deviation [SD] 8.9), and the average baseline prostate volume was 74.1 cc (SD 34.4). Mean IPSS scores improved from 22 at baseline to 9.8 at 36 months. IPSS QoL scores improved from 4.5 to 1.9. Qmax increased from 8.6 ml/s at baseline to 15 ml/s at 24 months and 12.1 ml/s at 36 months. PVR decreased from 134.9 ml to 38.5 ml. There were no significant changes in IIEF or MSHQ-EjD domains.
CONCLUSIONS
Rezūm WVTT provides significant, durable symptom…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 712 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.